LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Bacteriophage Protein Shows Antibiotic Potential

By LabMedica International staff writers
Posted on 27 Nov 2013
Image: Electron micrograph of bacteriophages attached to a bacterial cell (Photo courtesy of Wikimedia Commons).
Image: Electron micrograph of bacteriophages attached to a bacterial cell (Photo courtesy of Wikimedia Commons).
The T7 bacteriophage produces a protein that blocks Escherichia coli cell division and has the potential of being developed into an antibiotic-replacing drug.

T7 produces over 100 progeny per host cell in less than 25 minutes. If the T7 phage infection completes a successful growth cycle, it invariably culminates in disintegration of the host cell. Bacteriophages take over host cell resources primarily via the activity of proteins expressed early in infection. One such protein produced by the T7 phage is called Gp0.4 (gene product 0.4).

Investigators at Tel Aviv University (Israel) and their colleagues at Duke University (Durham, NC, USA) reported in the November 11, 2013, online edition of the journal, Proceedings of the National Academy of Sciences of the United States of America (PNAS) that Gp0.4 was a direct inhibitor of the E. coli filamenting temperature-sensitive mutant Z division protein.

They showed that a chemically synthesized Gp0.4 bound to purified filamenting temperature-sensitive mutant Z protein and directly inhibited its assembly in vitro. Consequently, expression of Gp0.4 in vivo was lethal to E. coli cultures and resulted in bacteria that were morphologically elongated. Furthermore, the inhibition of cell division by Gp0.4 enhanced the bacteriophage’s competitive ability by enabling them to maximize their progeny number by inhibiting escape of the daughter cells of the infected bacteria.

“Bacteria are infested with bacteriophages, which are their natural enemies and which in most cases destroy them,” said senior author Dr. Udi Qimron, professor of clinical microbiology and immunology at Tel Aviv University. “Ever since the discovery of bacteriophages in the early 20th century, scientists have understood that, on the principle of the "enemy of your enemy is your friend"; medical use could be made of phages to fight bacteria.”

“GP0.4 impedes cell division in the E. coli cell. With its capacity for cell division blocked, the bacterium continues to elongate until it dies,” said Dr. Qimron. “Potentially, this protein could be the ideal antibiotic.”

Related Links:

Tel Aviv University
Duke University


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Alcohol Testing Device
Dräger Alcotest 7000
Human Estradiol Assay
Human Estradiol CLIA Kit

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more